БЕЗОПАСНОСТЬ И ПЕРЕНОСИМОСТЬ ЭСЛИКАРБАЗЕПИНА АЦЕТАТА

1. Инструкция по медицинскому применению препарата Эксалиеф.

2. Almeida L., Bialer M., Soares-da-Silva P. Eslicarbazepine acetate. In: Shorvon S.D., Perucca E., Engel J. Jr., eds. The Treatment of Epilepsy. 3rd ed. Oxford: Wiley-Blackwell; 2009:485-98.

3. Ben-Menachem E., Gabbai A.A., Hufnager A. et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010; 89: 278-85.

4. Bialer M., Soares-da-Silva P. Pharmaco-kinetics and drug interactions of Eslicarbazepine acetate. Epilepsia. 2012; 53: 935-46.

5. Elger C., Halász P., Maia J. et al. Efficacy and safety of Eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebocontrolled, parallel-group phase III study. Epilepsia. 2009; 50: 454-63.

6. Gil-Nagel A., Elger C., Ben-Menachem E. et al. Efficacy and safety of Eslicarbazepine acetate as add-on treatment in patients with focalonset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia 2013; 54: 98-107.

7. Gil-Nagel A., Lopes-Lima J., Almeida L. et al. Efficacy and safety of 800 and 1200mg Eslicarbazepine acetate as adjunctive treatment in adults with refractory partial onset epilepsy. Acta Neurol Scand. 2009; 120: 281-7.

8. Glauser T.A. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy. 2001; 21: 904-19.

9. Guekht A., Gama H., Öztiryaki A.H. et al. Incidence of adverse events in relation to starting dose and titration regimen of Eslicarbazepine acetate as add-on treatment in patients with partial-onset seizures. Epilepsia. 2011; 52 (6): 108.

10. Halász P., Cramer J.A., Hodoba D. et al. Long-term efficacy and safety of Eslicarbazepine acetate: results of a 1-year openlabel extension study in partial-onset seizures in adults with epilepsy. Epilepsia. 2010; 51: 1963-9.

11. Nunes T., Rocha J., Falcão A. et al. Steadystate plasma and cerebrospinal fluid pharmacokinetics and tolerability of Eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia. 2013; 54: 108-116.